相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prednisone Has No Effect on the Pharmacokinetics of CYP3A4 Metabolized Drugs - Midazolam and Odanacatib
Eugene E. Marcantonio et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Disposition and Metabolism of the Cathepsin K Inhibitor Odanacatib in Humans
Kelem Kassahun et al.
DRUG METABOLISM AND DISPOSITION (2014)
Comparison of Endogenous 4β-Hydroxycholesterol with Midazolam as Markers for CYP3A4 Induction by Rifampicin
Linda Bjorkhem-Bergman et al.
DRUG METABOLISM AND DISPOSITION (2013)
Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Five Years of Continued Therapy in a Phase 2 Study
Bente Langdahl et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
4β-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans
Ulf Diczfalusy et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug-Drug Interaction Trial Design
M. L. Reitman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Three-Year Continued Therapy and Resolution of Effect
John A. Eisman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis
Aline G. Costa et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
Does the Long Plasma Half-Life of 4β-Hydroxycholesterol Impact Its Utility as a Cytochrome P450 3A (CYP3A) Metric?
Zheng Yang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
4 beta-Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin
Ulf Diczfalusy et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective
Valeria Chu et al.
DRUG METABOLISM AND DISPOSITION (2009)
Update on rifampin and rifabutin drug interactions
Anne M. Baciewicz et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2008)
Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol
K. P. Kanebratt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Cathepsin K inhibitors: A novel target for osteoporosis therapy
S. A. Stoch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Emerging roles of cysteine cathepsins in disease and their potential as drug targets
Olga Vasiljeva et al.
CURRENT PHARMACEUTICAL DESIGN (2007)
Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers
D. M. Burger et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
The role of cathepsins in osteoporosis and arthritis:: Rationale for the design of new therapeutics
Y Yasuda et al.
ADVANCED DRUG DELIVERY REVIEWS (2005)
The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity
JC Gorski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Pharmacokinetic interactions with rifampicin - Clinical relevance
M Niemi et al.
CLINICAL PHARMACOKINETICS (2003)
PXR, CAR and drug metabolism
TM Willson et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin
A Asghar et al.
DRUG METABOLISM AND DISPOSITION (2002)
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials
WJ Burman et al.
CLINICAL PHARMACOKINETICS (2001)
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride
M Niemi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
分享论文
